ZYDUSLIFE — Zydus Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Zydus Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	C2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	151,099	172,374	195,474	232,415	271,484
Cost of Revenue
Gross Profit	88,614	101,811	125,064	160,103	198,558
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	125,231	149,888	150,259	174,818	218,784
Operating Profit	25,868	22,486	45,215	57,597	52,700
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	28,381	25,897	48,089	60,267	66,211
Provision for Income Taxes
Net Income After Taxes	23,264	20,019	38,314	46,148	50,264
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	44,873	19,603	38,595	45,255	50,400
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	44,873	19,603	38,595	45,255	50,400
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	21	23.8	37.9	46.4	54
Dividends per Share